Prior to joining Selecta Biosciences, Dr. Cautreels was CEO of Solvay Pharmaceuticals, the pharmaceuticals division of the Solvay Group (Brussels, Belgium) until Solvay Pharmaceuticals was acquired by Abbott Laboratories in February 2010. Before becoming the CEO of Solvay Pharmaceuticals, Dr. Cautreels was their Global Head of R&D. Prior to joining Solvay, he was employed by Sanofi, Sterling-Winthrop, and Nycomed-Amersham in a variety of R&D management positions in Europe and in the United States. Dr. Cautreels was a director of Innogenetics NV (Gent, Belgium) and of Arqule Inc. (Woburn, MA, USA) from 1999-2006. He is currently a director of Selecta and Galapagos NV (Mechelen, Belgium). He was the President of the Belgian-Luxemburg Chamber of Commerce for Russia and Belarus until June 2010. He was born in Antwerp, Belgium, and graduated from the University of Antwerp, gaining a Doctorate in Chemistry, specializing in Mass Spectrometry. He received his management education from the Harvard Business School.
Prior to joining Selecta Biosciences, Dr. Johnston was Vice President of Operations for Alkermes having responsibilities for process development, scale-up, and clinical manufacturing for pulmonary and sustained release injectable products as well as leadership of Alkermes 90,000 square foot manufacturing facility in Chelsea, MA. Dr. Johnston was also a project leader and member of Steering Committees for numerous products through various stages of development from Phase 1 through registration. Dr. Johnston was an original member of Advanced Inhalation Research (AIR®) Inc., a private company acquired by Alkermes in 1999. Prior to joining AIR, Lloyd was a professor in the Department of Chemical Engineering at the University of New South Wales in Sydney, Australia. He received his B.S. in Chemical Engineering from Queen's University in Canada, and his M.S. and Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology.
Prior to joining Selecta Dr. Kishimoto was Vice President of Research at Momenta where he led a multidisciplinary team in advancing both novel and complex generic products for inflammation, oncology, and cardiovascular disease. Previously he was Senior Director of Inflammation Research at Millennium Pharmaceuticals, where he provided the scientific leadership for four programs in clinical development, and an Associate Director of Research at Boehringer Ingelheim. Dr. Kishimoto has published over 50 peer-reviewed articles in scientific journals, including Nature, Science, Cell, and the New England Journal of Medicine. Dr. Kishimoto received his B.A. from New College and his doctoral degree in Immunology from Harvard University.
Mr. Keller joined Selecta Biosciences from Abbott Laboratories in February 2011. After the acquisition of Solvay Pharmaceuticals by Abbott Laboratories, he led the integration process for five R&D and Manufacturing facilities in Europe. Before the acquisition, Mr. Keller was VP for Business Development and Alliance Management at Solvay Pharmaceuticals where he negotiated license and acquisition agreements in various therapeutic areas such as vaccines, neurology, and cardiology. He was the lead negotiator for the $1.5 billion fenofibrate alliance between Solvay Pharmaceuticals and Abbott Laboratories. Mr. Keller also gained almost ten years of experience in management consulting with McKinsey & Company and Simon Kucher and Partners. He has worked with five of the ten biggest pharmaceutical companies and specialized in marketing strategy and M&A transactions. Mr. Keller holds a Masters degree of Industrial Engineering and Management from the University of Karlsruhe, Germany.
Prior to joining Selecta Biosciences, Mr. Abraham was Executive Director for Patents at Durect Corporation, a small-cap specialty pharmaceutical company. Previously, he was Senior Patent Counsel for ALZA Corporation, a Johnson & Johnson company. Prior to working in-house at Durect and J&J, Mr. Abraham was employed by the law firms of Wilson Sonsini Goodrich and Rosati, and Finnegan Henderson Farabow Garrett and Dunner. David also was a Patent Examiner at the United States Patent and Trademark Office. A specialist in both building field-defining patent portfolios for life sciences companies and negotiating complex partnering transactions, David has experience advising clients ranging from early stage startups to Big Pharma on intellectual property strategy and on transactional matters. David received his B.S. in Chemical Engineering from the University of Rochester and his J.D. from the George Washington School of Law.
Mr. Siewers has 30 years of experience in financial management, financial systems design and implementation, equity and debt financing, and mergers and acquisitions. Prior to joining Selecta, Mr. Siewers was an independent consultant for eight years providing strategic guidance and tactical implementation of accounting systems, management and regulatory reporting, internal controls, profitability and cost analysis to an array of clients ranging from startups to mid-level companies. Previously, David spent over 20 years in the financial services arena as CFO/SVP of Fleet Services Corporation and SVP of Putnam Investments. David graduated from Marietta College and received his CPA in 1978 while working at KPMG.